| Name | Title | Contact Details |
|---|
Xiros turn bright ideas into brilliant implants. We are on a mission to improve patient outcomes by creating innovative implantable textiles and devices.
AutoCruitment is a metrics-driven ecosystem of patient recruitment and engagement solutions, digitizing and revolutionizing the end-to-end patient and client experience. Our multifaceted approach utilizes sophisticated algorithms, advanced automation, and over 1,500 direct-to-patient online channels to find, screen, and automatically refer highly qualified patients with a greater chance of randomization success. The results are higher enrollment and greater patient engagement, accelerating timelines and exceeding milestones at every phase of clinical research. The AutoCruitment Difference: •Targeted: The AutoCruitment platform`s proprietary algorithms and innovative approach help precisely target your ideal patient population, reaching over 247 million patients to date •Experienced: AutoCruitment has completed over 578 studies and has a continuously learning and growing database of over 10 million patients •Technology-Enabled: The AutoCruitment platform utilizes advanced online screeners to simultaneously screen for multiple studies and provide customized cohort volumes based on your project`s needs •Volume- and Quality-Focused: The far-reaching power of the AutoCruitment platform and our direct-to-patient methodology excels at attracting and retaining optimal volumes of highly qualified patients •Transparent: The AutoCruitment portal and its robust reporting capabilities enable complete and real-time transparency from the very beginning •Metrics-Driven: Our patient recruitment scientists work in complete collaboration with your study teams and research sites to optimize the program and increase randomization by an average of 97% per month AutoCruitment delivers something different. Our comprehensive ecosystem of scalable solutions offers a 3-day startup time and swiftly removes the recruitment barrier for biotech innovations and pharmaceutical research, shortening timelines and trimming budgets for a quicker, smoother path to market.
At Nestlé Health Science, we’re advancing nutritional therapy to change the approach of managing your health. Behind our pioneering company are people who are driving breakthroughs and innovating for impact. Here, you have the chance to change the course of health and your career. Our people are exploring new territory and breaking new ground in areas such as GI, critical care, surgery, oncology, healthy ageing, food allergy, obesity, brain health and pediatrics. They are changing the way doctors think about meeting the nutritional needs of patients, and the way patients and consumers manage their own health. They know the faces, hear the stories and celebrate the successes of people who had their lives transformed thanks to Nestlé Health Science solutions. Be part of a journey that changes the course of health.
arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.
With over 25 years of experience, MEDISCA has developed a solid reputation as an innovative and entrepreneurial company in the pharmaceutical compounding industry.